Loading...
Loading...
ELOX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 11.0M |
| Operating I/L | -11.0M |
| Other Income/Expense | -0.7M |
| Interest Income | 0.0M |
| Pretax | -11.6M |
| Income Tax Expense | 0.3M |
| Net Income/Loss | -11.9M |
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in ribosome modulation for rare and ultra-rare premature stop codon diseases. Their lead drug candidate, ELX-02, is in Phase 2 clinical trial for cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also focuses on preclinical programs for alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as earlier discovery stage programs in oncology.
